Antiretroviral Agents in HIV-1 (2014)

DHHS Adult HIV 2014

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/282343

Contents of this Issue

Navigation

Page 3 of 23

Selecting a Treatment Regimen Table 2. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy ARV Class ARV Agent(s) Advantages Disadvantages Dual- NRTI Pairs ABC/3TC • Once-daily dosing • No food effect • No nephrotoxicity • Inferior virologic responses in patients with baseline HIV RNA ≥100,000 copies/mL when given with EFV or ATV/r as compared with TDF/FTC in ACTG 5202 study. This difference not seen when ABC/3TC was used in combination with DTG. • Requires HLA-B*5701 testing before use • Potential for ABC HSR in patients with HLA-B*5701 allele • ABC use has been associated with cardiac events in some but not all observational studies. TDF/FTC • Better virologic responses than with ABC/3TC in patients with baseline viral load ≥100,000 copies/mL when combined with ATV/r or EFV • Active against HBV; recommended dual- NRTI for HIV/HBV co-infected patients • Once-daily dosing • No food effect • Co-formulated in fixed-dose combinations that comprise an entire regimen in a single pill (EFV/TDF/FTC, EVG/ cobi/TDF/FTC, and RPV/TDF/FTC) • Potential for renal impairment, including proximal tubulopathy and acute or chronic renal insufficiency • Potential for decrease in BMD 2

Articles in this issue

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 (2014) - DHHS Adult HIV 2014